BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Boehringer Ingelheim logo

Boehringer Ingelheim

Status and phase

Completed
Phase 1

Conditions

Ovarian Neoplasms
Peritoneal Neoplasms

Treatments

Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Drug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

Study type

Interventional

Funder types

Industry

Identifiers

NCT01314105
1199.119
2010-022523-30 (EudraCT Number)

Details and patient eligibility

About

This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive relapsed ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer.

Enrollment

19 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female patients, age 18 years or older, with a first, second or third relapse of histologically (on initial diagnosis) confirmed epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer
  • Up to three lines of prior chemo (chemotherapy before and after interval surgery to be counted as one line therapy), with treatment free interval of > 6 months (= time between last administration of prior anti-cancer treatment, including chemotherapy, hormonal therapy, or radiation therapy, and diagnosis of progressive disease)
  • Platinum based chemo in immediately preceding line
  • Eligibility for treatment with i.v. chemotherapy regimen of carboplatin AUC 5 and PLD 30 mg/m2 every 4 weeks
  • Life expectancy of at least 3 months
  • Written informed consent that is consistent with International Conference of Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance score 0 or1
  • Prior treatment with angiogenesis inhibitor (bevacizumab, TKI inhibiting VEGFR-2) is allowed provided treatment with bevacizumab has been discontinued = 28 days prior to start of therapy and treatment with the TKI has been discontinued = 3 months prior to start of therapy, provided anti-angiogenic therapy was added to only one of the preceding lines of therapy

Exclusion criteria

  • Prior chemotherapy with doxorubicin (any formulation, liposomal or non-liposomal doxorubicin).
  • Any contraindications for therapy with PLD or carboplatin, e.g. a history of hypersensitivity reactions to platinum-containing compounds and their excipients.
  • Hypersensitivity to active substance or to any of the excipients of BIBF 1120.
  • Treatment with other investigational drugs or participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial (exception: for previous treatment with angiogenesis inhibitors, cf. inclusion criterion #8).
  • Laboratory values indicating an increased risk for adverse events.
  • Major surgery within 4 weeks prior to start of study treatment.
  • Patients for whom surgery is planned, e.g. interval debulking surgery.
  • Clinically relevant non-healing wound, ulcer (intestinal tract, skin) or bone fracture.
  • Clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition or hydration.
  • Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.
  • History of clinical symptoms of brain metastases.
  • Prior thrombosis or thromboembolic event in the presence of an inherited coagulopathy.
  • History of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months.
  • Known inherited or acquired bleeding disorder.
  • Significant cardiovascular diseases.
  • Serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy.
  • Other malignancy diagnosed within the past 5 years.
  • Known serious illness or concomitant non-oncological disease.
  • Patients unable to comply with the protocol.
  • Patients with preserved reproductive capacity who are sexually active and unwilling to use a medically acceptable method of contraception.
  • Pregnancy or breast feeding.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

19 participants in 3 patient groups

BIBF 1120 L+ Carboplatin + PLD
Experimental group
Description:
BIBF 1120 (100 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
Treatment:
Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
BIBF 1120 M + Carboplatin + PLD
Experimental group
Description:
BIBF 1120 (150 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
Treatment:
Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
BIBF 1120 H + Carboplatin + PLD
Experimental group
Description:
BIBF 1120 (200 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
Treatment:
Drug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems